Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer
Authors:
- Nicole UrbanNUNicole Urban
- Jason D. ThorpeJTJason D. Thorpe
- Lindsay A. BerganLBLindsay A. Bergan
- Robin M. ForrestRFRobin M. Forrest
- Archana V. KampaniAKArchana V. Kampani
- Nathalie SchollerNSNathalie Scholler
- Kathy C. O’briantKOKathy C. O’briant
- Garnet L. AndersonGAGarnet L. Anderson
- Daniel W. CramerDCDaniel W. Cramer
- Christine D. BergCBChristine D. Berg
- Martin W. McIntoshMMMartin W. McIntosh
- Patricia HartgePHPatricia Hartge
Open Access
- 14 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 103 (21) , 1630-1634
Abstract
In screening for epithelial ovarian cancer, unnecessary surgery can be reduced by limiting use of transvaginal ultrasound (TVU) to women with increasing CA125 serum levels. Replacing or augmenting TVU with measurement of a serum marker specific for malignancy might further improve screening performance. Serum samples from 112 invasive ovarian cancer patients and 706 matched control subjects from the Prostate, Lung, Colorectal, and Ovarian trial were used to evaluate human epididymis protein 4 (HE4), mesothelin, matrix metalloproteinase 7 (MMP7), SLPI, Spondin2, and insulin-like growth factor binding protein 2 (IGFBP2) for their potential use in screening. TVU results were available for a subset of 84 patients and 516 control subjects used to compare the best marker with TVU. HE4 was found to perform better than TVU as a second-line screen, confirming 27 of 39 cancers with increasing CA125 serum levels compared with 17 cancers confirmed by TVU ( P = .03). Serum HE4 levels were found to increase with age and smoking status, suggesting that a longitudinal algorithm might improve its performance.Keywords
This publication has 16 references indexed in Scilit:
- Effect of Screening on Ovarian Cancer MortalityJAMA, 2011
- Results From Four Rounds of Ovarian Cancer Screening in a Randomized TrialObstetrics & Gynecology, 2009
- Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening TrialGynecologic Oncology, 2008
- Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrenceGynecologic Oncology, 2008
- Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian CancerPLOS ONE, 2008
- Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancerGynecologic Oncology, 2007
- Identification of genes associated with ovarian cancer metastasis using microarray expression analysisInternational Journal of Gynecological Cancer, 2006
- Generating longitudinal screening algorithms using novel biomarkers for disease.2002
- The Efficacy of a Sonographic Morphology Index in Identifying Ovarian Cancer: A Multi-institutional InvestigationGynecologic Oncology, 1994